| Serial Number | 98104260 |
| Word Mark | ACCOMPLISH |
| Filing Date | Thursday, July 27, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Wednesday, April 3, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 7, 2024 |
| Goods and Services | conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention deficit hyperactivity disorder (ADHD) |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, August 27, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Cingulate Therapeutics LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Kansas City, KS 66205 |
| Event Date | Event Description |
| Monday, April 1, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, March 29, 2024 | ASSIGNED TO EXAMINER |
| Sunday, August 27, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, July 31, 2023 | NEW APPLICATION ENTERED |